PDS Biotechnology Corporation (PDSB) News
Follow PDS Biotechnology Corporation (PDSB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Weekly Recap: PDS0101+pembrolizumab Phase 2 OS and Nant Capital $22.3M PIPE
PDS Biotechnology Corp. (NASDAQ:PDSB) reported Phase 2 PDS0101+pembrolizumab results showing 39.3—month median OS in 1L ICI—naïve CPS≥1 patients, 36% ORR and 13.8% Grade≥3 TRAEs, while PDS0301 showed strong survival; the
NEWS | Sep 28, 2026, 11:06 AM UTC
L
PDSB - PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16- Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology
PDSB - PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16- Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology
NEWS | Sep 22, 2026, 12:01 PM UTC
L
PDS Biotechnology Retires Yorkville $6M Note Early With $4.6M Redemption
PDS Biotechnology redeemed in full its promissory note with Yorkville on Sep 14, 2026, paying approximately $4.6 million to cover all outstanding principal and accrued interest. The $6.0 million note, issued on Jun 15, 2
CENTRAL_BANK | Sep 14, 2026, 08:16 PM UTC
L
PDS Biotechnology appoints Patrick Soon-Shiong and James Banaag to board
PDS Biotechnology appointed Dr. Patrick Soon-Shiong and James Banaag to its Board of Directors, effective September 14, 2026.Original SEC Filing: PDS Biotechnology Corp [ PDSB ] - 8-K - Sep. 14, 2026This is an AI-powered
REGULATION | Sep 14, 2026, 08:16 PM UTC
M
PDS Biotech completes initial closing of up to $22.3M PIPE
PDS Biotech announced the initial closing of a PIPE financing of up to $22.3 million and the appointment of Dr. Patrick Soon-Shiong to its board.
EQUITY | Sep 14, 2026, 02:30 PM UTC
L
PDS Biotechnology price target cut to $5.00 from $7.00
HC Wainwright & Co. cut its price target on PDS Biotechnology to $5.00 per share from $7.00, according to Benzinga’s ratings actions.
EQUITY | Sep 08, 2026, 05:34 PM UTC
M
PDS Biotechnology PIPE targets ~$11.55M; Nant/AB $11M FDA milestone commitment
PDS Biotechnology said its private placement is expected to raise approximately $11.55 million at the initial closing. Nant and AB Group committed an additional $11 million milestone tranche upon FDA submission of a Phas
REGULATION | Sep 08, 2026, 12:44 PM UTC
L
PDS Biotech price target kept at $7.00 by HC Wainwright
HC Wainwright & Co. maintained its price target for PDS Biotechnology at $7.00 per share, according to TradingView News.
EQUITY | Aug 26, 2026, 11:38 AM UTC
L
PDS Biotech reports Second Quarter 2026 financial results
PDS Biotech (PDSB) reports its Second Quarter 2026 financial results, per TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 12:30 PM UTC
L
PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program
PDS Biotechnology Corporation (NASDAQ: PDSB ) shares have fallen by about 67% on Tuesday as the company announced a strategic refocus on its PDS0301 program for metastatic colorectal cancer. PDS0301 Metastatic Colorectal
EQUITY | Aug 11, 2026, 05:49 PM UTC